Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer

被引:56
作者
Xu, Yan [1 ]
Zhao, Ai Guang [1 ]
Li, Zhao Yan [1 ]
Zhao, Gang [2 ]
Cai, Yong [3 ]
Zhu, Xiao Hong [1 ]
Cao, Ni Da [1 ]
Yang, Jin Kun [1 ]
Zheng, Jian [1 ]
Gu, Yin [1 ]
Han, Ying Ying [1 ]
Zhu, Ying Jie [1 ]
Yang, Jin Zu [1 ]
Gao, Feng [1 ]
Wang, Qiang [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Dept Oncol, Longhua Hosp, Shanghai 200032, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Renji Hosp, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Dept Prevent Med, Sch Publ Hlth, Shanghai 200030, Peoples R China
基金
上海市自然科学基金;
关键词
gastric cancer; overall survival; traditional Chinese medicine; prospective study; Cox proportional hazard regression model; PHASE-III TRIAL; 1ST-LINE THERAPY; NUDE-MICE; CISPLATIN; ADENOCARCINOMA; JUNCTION; PLUS; FLUOROURACIL; CHEMOTHERAPY; OXALIPLATIN;
D O I
10.1177/1534735412450512
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang' An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan-Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.
引用
收藏
页码:414 / 422
页数:9
相关论文
共 18 条
[1]   Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].
Al-Batran, Salah-Eddin ;
Hartmann, Joerg Thomas ;
Probst, Stephan ;
Schmalenberg, Harald ;
Hollerbach, Stephan ;
Hofheinz, Ralf ;
Rethwisch, Volker ;
Seipelt, Gernot ;
Homann, Nils ;
Wilhelm, Gerhard ;
Schuch, Gunter ;
Stoehlmacher, Jan ;
Derigs, Hans Guenter ;
Hegewisch-Becker, Susanna ;
Grossmann, Johannes ;
Pauligk, Claudia ;
Atmaca, Akin ;
Bokemeyer, Carsten ;
Knuth, Alexander ;
Jaeger, Elke .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442
[2]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[3]  
Cao Ni-da, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P116
[4]   Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].
Cunningham, David ;
Starling, Naureen ;
Rao, Sheela ;
Iveson, Timothy ;
Nicolson, Marianne ;
Coxon, Fareeda ;
Middleton, Gary ;
Daniel, Francis ;
Oates, Jacqueline ;
Norman, Andrew Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46
[5]   Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction [J].
Dank, M. ;
Zaluski, J. ;
Barone, C. ;
Valvere, V. ;
Yalcin, S. ;
Peschel, C. ;
Wenczl, M. ;
Goker, E. ;
Cisar, L. ;
Wang, K. ;
Bugat, R. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1450-1457
[6]   Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer [J].
Han, S-W ;
Oh, D-Y ;
Im, S-A ;
Park, S. R. ;
Lee, K-W ;
Song, H. S. ;
Lee, N-S ;
Lee, K. H. ;
Choi, I. S. ;
Lee, M. H. ;
Kim, M. A. ;
Kim, W. H. ;
Bang, Y-J ;
Kim, T-Y .
BRITISH JOURNAL OF CANCER, 2009, 100 (02) :298-304
[7]   Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world [J].
Kamangar, Farin ;
Dores, Graca M. ;
Anderson, William F. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2137-2150
[8]   S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial [J].
Koizumi, Wasaburo ;
Narahara, Hiroyuki ;
Hara, Takuo ;
Takagane, Akinori ;
Akiya, Toshikazu ;
Takagi, Masakazu ;
Miyashita, Kosei ;
Nishizaki, Takashi ;
Kobayashi, Osamu ;
Takiyama, Wataru ;
Toh, Yasushi ;
Nagaie, Takashi ;
Takagi, Seiichi ;
Yamamura, Yoshitaka ;
Yanaoka, Kimihiko ;
Orita, Hiroyuki ;
Takeuchi, Masahiro .
LANCET ONCOLOGY, 2008, 9 (03) :215-221
[9]   Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. [J].
Macdonald, JS ;
Smalley, SR ;
Benedetti, J ;
Hundahl, SA ;
Estes, NC ;
Stemmermann, GN ;
Haller, DG ;
Ajani, JA ;
Gunderson, LL ;
Jessup, JM ;
Martenson, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :725-730
[10]   Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].
Ohtsu, Atsushi ;
Shah, Manish A. ;
Van Cutsem, Eric ;
Rha, Sun Young ;
Sawaki, Akira ;
Park, Sook Ryun ;
Lim, Ho Yeong ;
Yamada, Yasuhide ;
Wu, Jian ;
Langer, Bernd ;
Starnawski, Michal ;
Kang, Yoon-Koo .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) :3968-3976